351 related articles for article (PubMed ID: 37046762)
1. The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions.
Kiousi DE; Kouroutzidou AZ; Neanidis K; Karavanis E; Matthaios D; Pappa A; Galanis A
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046762
[TBL] [Abstract][Full Text] [Related]
2. Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors.
Huang J; Gong C; Zhou A
Ther Adv Med Oncol; 2023; 15():17588359231204854. PubMed ID: 37841750
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.
Lu Y; Yuan X; Wang M; He Z; Li H; Wang J; Li Q
J Hematol Oncol; 2022 Apr; 15(1):47. PubMed ID: 35488243
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
5. Microbiome bacterial influencers of host immunity and response to immunotherapy.
Yousefi Y; Baines KJ; Maleki Vareki S
Cell Rep Med; 2024 Apr; 5(4):101487. PubMed ID: 38547865
[TBL] [Abstract][Full Text] [Related]
6. Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend?
Zhao H; Wang D; Zhang Z; Xian J; Bai X
Molecules; 2022 Jul; 27(15):. PubMed ID: 35956752
[TBL] [Abstract][Full Text] [Related]
7. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes.
Ting NL; Lau HC; Yu J
Gut; 2022 Jul; 71(7):1412-1425. PubMed ID: 35277453
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota interactions with antitumor immunity in colorectal cancer: From understanding to application.
Zhuang YP; Zhou HL; Chen HB; Zheng MY; Liang YW; Gu YT; Li WT; Qiu WL; Zhou HG
Biomed Pharmacother; 2023 Sep; 165():115040. PubMed ID: 37364479
[TBL] [Abstract][Full Text] [Related]
9. Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality.
Guillot N; Roméo B; Manesh SS; Milano G; Brest P; Zitvogel L; Hofman P; Mograbi B
Trends Mol Med; 2023 Nov; 29(11):897-911. PubMed ID: 37704493
[TBL] [Abstract][Full Text] [Related]
10. Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review.
Huang C; Li M; Liu B; Zhu H; Dai Q; Fan X; Mehta K; Huang C; Neupane P; Wang F; Sun W; Umar S; Zhong C; Zhang J
Front Oncol; 2021; 11():642110. PubMed ID: 33816289
[No Abstract] [Full Text] [Related]
11. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
12. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
Renga G; Nunzi E; Pariano M; Puccetti M; Bellet MM; Pieraccini G; D'Onofrio F; Santarelli I; Stincardini C; Aversa F; Riuzzi F; Antognelli C; Gargaro M; Bereshchenko O; Ricci M; Giovagnoli S; Romani L; Costantini C
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236743
[TBL] [Abstract][Full Text] [Related]
13. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
Najafi S; Majidpoor J; Mortezaee K
Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
[TBL] [Abstract][Full Text] [Related]
14. Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy.
Tian M; Zhang S; Tseng Y; Shen X; Dong L; Xue R
Anticancer Agents Med Chem; 2022; 22(7):1244-1256. PubMed ID: 34229597
[TBL] [Abstract][Full Text] [Related]
15. The role of gut microbiome in immune modulation in metastatic renal cell carcinoma.
Deluce J; Maleki Vareki S; Fernandes R
Ther Adv Med Oncol; 2022; 14():17588359221122714. PubMed ID: 36105887
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiome in modulating immune checkpoint inhibitors.
Li X; Zhang S; Guo G; Han J; Yu J
EBioMedicine; 2022 Aug; 82():104163. PubMed ID: 35841869
[TBL] [Abstract][Full Text] [Related]
17. The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era.
Spyrou N; Vallianou N; Kadillari J; Dalamaga M
Semin Cancer Biol; 2021 Aug; 73():356-376. PubMed ID: 33989733
[TBL] [Abstract][Full Text] [Related]
18. Complex interactions between the microbiome and cancer immune therapy.
Schwartz DJ; Rebeck ON; Dantas G
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):567-585. PubMed ID: 31526274
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review).
Jiang H; Zhang Q
Oncol Lett; 2024 Feb; 27(2):87. PubMed ID: 38249807
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation-A Special Reference to Colorectal Cancer.
Koulouridi A; Messaritakis I; Gouvas N; Tsiaoussis J; Souglakos J
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
